<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">Also, many evidences showed that convalescent plasma from patients recovering from viral infections can be used as a treatment in patients infected with SARS-CoV-2 (
 <xref rid="bb0055" ref-type="bibr">Chen et al., 2020</xref>). In addition, by influencing ACE2 levels, cardiovascular diseases and/or their treatment can play an important role in the infectivity and consequences of COVID - 19. Whether ACE2 treatment or upregulation caused by the disease immediately affects the COVID - 19 course (
 <xref rid="bb0230" ref-type="bibr">Sommerstein et al., 2020</xref>). During this global emergency of the COVID-19 pandemic, strategies are taken into account to quickly monitor the timeline for licensing a vaccine against COVID-19, especially by compressing the generally long duration of phase IIâ€“III study (
 <xref rid="bb0035" ref-type="bibr">Callaway, 2020</xref>; 
 <xref rid="bb0075" ref-type="bibr">De Wit et al., 2020</xref>; 
 <xref rid="bb0025" ref-type="bibr">Boodman, 2020</xref>; 
 <xref rid="bb0085" ref-type="bibr">Eyal et al., 2020</xref>).
</p>
